Pfizer Inc. (PFE)
Company Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.
In addition, the company is involved in the contract manufacturing business.
It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Country | United States |
IPO Date | Jun 1, 1972 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 81,000 |
CEO | Dr. Albert Bourla D.V.M., Ph.D. |
Contact Details
Address: 235 East 42nd Street New York, New York United States | |
Website | https://www.pfizer.com |
Stock Details
Ticker Symbol | PFE |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000078003 |
CUSIP Number | 717081103 |
ISIN Number | US7170811035 |
Employer ID | 13-5315170 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & Chief Executive Officer |
David M. Denton | Chief Financial Officer & Executive Vice President |
Douglas M. Lankler | Executive Vice President & Chief Legal Officer |
Dr. Chris Boshoff FMedSci, M.D., Ph.D. | Chief Scientific Officer and President of Research & Development |
Dr. Michael S. Vincent M.D., Ph.D. | Senior Vice President and Chief Scientific Officer of Inflammation & Immunology |
Francesca M. DeMartino | Chief Investor Relations Officer |
Jennifer B. Damico | Senior Vice President, Controller & Principal Accounting Officer |
Lidia L. Fonseca | Executive Vice President and Chief Digital & Technology Officer |
Payal Sahni Becher | Chief People Experience Officer & Executive Vice President |
Sally M. Susman | Executive Vice President & Chief Corporate Affairs Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 18, 2025 | 4 | Filing |
Mar 13, 2025 | ARS | Filing |
Mar 13, 2025 | DEFA14A | Filing |
Mar 13, 2025 | DEF 14A | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |